The Role of RWD in the Development of Remdesivir

Matt Bryant has been a visionary and driving force around transforming the patient experience in clinical trials for nearly a decade. His background in Computer Science and Business has supported nearly two decades of clinical development expertise to deliver numerous products and applications serving patients, investigators, and biopharma enterprises. In addition to holding a variety of roles in clinical development, innovation, technology and design at Eli Lilly, Amgen and currently, Gilead Sciences, Mr Bryant has created new ventures such as being a founding member of the direct-to-patient startup, Lightship backed by Khosla Ventures, McKesson Ventures, Define Ventures, Brook Byers and Marc Benioff. Mr Bryant has lived and worked in the largest pharmaceutical markets globally, spending extensive time with patients, caregivers, investigators and regulatory agencies to listen and act on the necessary infrastructure to evolve how clinical programs are designed and delivered.

Anand Chokkalingam is Executive Director and Head of the Real World Evidence team for Gilead’s Virology Therapeutic Area, encompassing HIV, viral hepatitis, and emerging infections including COVID-19. At Gilead, Mr Chokkalingam has also served in Clinical Development, where he led drug development teams for COVID-19 and HCV, and prior to that served as Head of the Epidemiology team for Gilead’s Liver Disease portfolio, leading post-authorization/post-marketing studies around the globe and applying pharmaco-epidemiology methods to real world data. Mr Chokkalingam is also an Associate Adjunct Professor of Epidemiology at the UC Berkeley School of Public Health. Mr Chokkalingam came to Gilead in 2013 after eight years on faculty at UC Berkeley, where his research focused on molecular and genetic epidemiology of childhood cancers and prostate cancer.Mr Chokkalingam has worked previously for several biotech and molecular diagnostics companies including Syva/Syntex, Celera, and Tethys. He has a BA in Biochemistry from UC Berkeley and a PhD in Epidemiology from the University of Maryland Baltimore, and he completed a postdoctoral fellowship in Cancer Epidemiology at the U.S. NCI’s Division of Cancer Epidemiology and Genetics.

Hassan Kadhim is the Business Engagement Leader for Clinical Operations and Development for Vertex Pharmaceuticals. Prior to this role, he was the Global Head of Clinical Trial Business Capabilities & Clinical Innovation at BMS, where his team governed the business technology capabilities strategy within Global Development Operations, and drove changes and innovation towards better outcomes for clinical trial stakeholders. Mr Kadhim is passionate about transforming the clinical research arena in the pharma industry through the use of technologies and patient-centric clinical trials, and is a firm believer of the need for clinical innovation grounded in strong business practices for sustainability, change management and adherence to compliance and regulatory commitments. Mr Kadhim regularly appears and speaks at industry events around improving the clinical trial experience with digital tools, and wrote “The Remote Clinical Trials Model” whitepaper in 2016, to formalize a new patient-centric clinical trial research model leading to what we know today as Decentralized Clinical Trials. Mr Kadhim actively collaborates across industry collaborations such as Transcelerate and others to advance relevant and high-value industry challenges.He has degrees in bioinformatics and pharmaceutical sciences, both from the University of Montreal in Canada.